NCT01895361View on ClinicalTrials.gov

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

PHASE2CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Sickle Cell Disease
Interventions
DRUG

SelG1

DRUG

Placebo

Trial Locations (56)

Unknown

Birmingham

Mobile

Little Rock

Los Angeles

Oakland

Orange

Sacramento

Aurora

New Haven

Washington D.C.

Daytona Beach

Jacksonville

Miami

Orlando

Tampa

Atlanta

Augusta

Chicago

Peoria

Indianapolis

Louisville

Baton Rouge

New Orleans

Baltimore

Bethesda

Boston

Detroit

Jackson

Kansas City

Las Vegas

New Brunswick

Newark

Brooklyn

New Hyde Park

The Bronx

Chapel Hill

Durham

Greenville

Cleveland

Columbus

Oklahoma City

Philadelphia

Pittsburgh

Charleston

Sumter

Fort Worth

Houston

Norfolk

Richmond

Salvador

Porto Alegre

Campinas

São José Do Rio Preto

Rio de Janeiro

São Paulo

Kingston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Food and Drug Administration (FDA)

FED

lead

Reprixys Pharmaceutical Corporation

INDUSTRY

NCT01895361 - Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises | Biotech Hunter | Biotech Hunter